Clinical Trials
21 trialsNCT06052306 2026-06-15
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer
Phase 1 Active not recruiting
NCT06909825 2026-06-09
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT03732820 2026-06-02
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT06031805 2026-06-02
PROWESs
AstraZeneca
Recruiting
NCT06228053 2026-06-02
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT06514521 2026-06-01
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
NCT06492122 2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT05682443 2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06533644 2026-05-18
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.
Phase 2 Recruiting
NCT07244341 2026-05-15
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT05125016 2026-05-05
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07365995 2026-05-05
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3 Recruiting
NCT07553988 2026-04-28
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
R-Pharm
Phase 2 Active not recruiting
NCT05457257 2026-04-21
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Active not recruiting
NCT06402331 2026-04-08
AlphaBreak
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT04853498 2026-03-31
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT05171816 2026-03-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca
Phase 3 Active not recruiting
NCT06380738 2025-12-26
PROceed
AstraZeneca
Recruiting
NCT06155084 2025-12-22
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Hinova Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT07172126 2025-09-15
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting